IL-27 Limits IL-2 Production during Th1 Differentiation1

Although the ability of IL-27 to promote T cell responses is well documented, the anti-inflammatory properties of this cytokine remain poorly understood. The current work demonstrates that during infection with Toxoplasma gondii, IL-27R-deficient mice generate aberrant IL-2 responses that are associated with the development of a lethal inflammatory disease. Because in vivo depletion of IL-2 prolongs the survival of infected IL-27R−/− mice, these data suggest that IL-27 curbs the development of immunopathology by limiting parasite-induced IL-2 production. Consistent with this hypothesis, IL-27R−/− CD4+ T cells produce more IL-2 than wild-type counterparts during in vitro differentiation, and when rIL-27 is introduced, it can suppress the expression of IL-2 mRNA and protein by the latter group. Additionally, these studies reveal that, like IL-27, IL-12 can inhibit IL-2 production, and although each employs distinct mechanisms, they can synergize to enhance the effect. In contrast, this property is not shared by closely related cytokines IL-6 and IL-23. Thus, while traditionally viewed as proinflammatory agents, the present findings establish that IL-27 and IL-12 cooperate to limit the availability of IL-2, a potent T cell growth and survival factor. Moreover, because the current studies demonstrate that both can induce expression of suppressor of cytokine signaling 3, a protein that tempers cytokine receptor signaling, they also suggest that IL-27 and IL-12 share additionally inhibitory properties.

[1]  M. Neurath,et al.  Impaired Th1 responses in mice deficient in Epstein‐Barr virus‐induced gene 3 and challenged with physiological doses of Leishmania major , 2005, European journal of immunology.

[2]  T. Mak,et al.  The IL-27 Receptor Chain WSX-1 Differentially Regulates Antibacterial Immunity and Survival during Experimental Tuberculosis 1 , 2005, The Journal of Immunology.

[3]  S. Khader,et al.  IL-27 Signaling Compromises Control of Bacterial Growth in Mycobacteria-Infected Mice1 , 2004, The Journal of Immunology.

[4]  G. Wu,et al.  The IL-27 Receptor (WSX-1) Is an Inhibitor of Innate and Adaptive Elements of Type 2 Immunity1 , 2004, The Journal of Immunology.

[5]  T. Yoshimoto,et al.  An Indispensable Role for STAT1 in IL-27-Induced T-bet Expression but Not Proliferation of Naive CD4+ T Cells1 , 2004, The Journal of Immunology.

[6]  C. Hunter,et al.  Biology of recently discovered cytokines: Discerning the pro- and anti-inflammatory properties of interleukin-27 , 2004, Arthritis research & therapy.

[7]  C. Hunter,et al.  Understanding the Pro- and Anti-Inflammatory Properties of IL-271 , 2004, The Journal of Immunology.

[8]  C. Hunter,et al.  Cutting Edge: Early IL-4 Production Governs the Requirement for IL-27-WSX-1 Signaling in the Development of Protective Th1 Cytokine Responses following Leishmania major Infection1 , 2004, The Journal of Immunology.

[9]  R. Schwartz,et al.  Smad3 Is Essential for TGF-β1 to Suppress IL-2 Production and TCR-Induced Proliferation, but Not IL-2-Induced Proliferation1 , 2004, The Journal of Immunology.

[10]  W. Alexander,et al.  The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. , 2004, Annual review of immunology.

[11]  T. Mcclanahan,et al.  WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27 , 2004, The Journal of Immunology.

[12]  F. D. de Sauvage,et al.  IL-27 regulates IL-12 responsiveness of naïve CD4+ T cells through Stat1-dependent and -independent mechanisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Szabo,et al.  Molecular mechanisms regulating Th1 immune responses. , 2003, Annual review of immunology.

[14]  T. Mak,et al.  The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. , 2003, Immunity.

[15]  G. Trinchieri,et al.  The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. , 2003, Immunity.

[16]  T. Mak,et al.  WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. , 2003, Immunity.

[17]  W. Paul,et al.  Stat5 activation plays a critical role in Th2 differentiation. , 2003, Immunity.

[18]  R. Kastelein,et al.  IL-27 and IFN-α Signal via Stat1 and Stat3 and Induce T-Bet and IL-12Rβ2 in Naive T Cells , 2003 .

[19]  S. Ebong,et al.  Suppressor of Cytokine Signaling 3 Regulates Proliferation and Activation of T-helper Cells* , 2003, Journal of Biological Chemistry.

[20]  J. Johnston,et al.  SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses , 2003, Nature Medicine.

[21]  R. Schwartz T cell anergy. , 2003, Annual review of immunology.

[22]  J. Johnston,et al.  A Role of Suppressor of Cytokine Signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated Interleukin 2 Production , 2003, The Journal of experimental medicine.

[23]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[24]  Ronald H. Schwartz,et al.  Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process , 2003, Nature Immunology.

[25]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[26]  C. Hunter,et al.  Susceptibility of Interleukin-2-Deficient Mice to Toxoplasma gondii Is Associated with a Defect in the Production of Gamma Interferon , 2002, Infection and Immunity.

[27]  D. Robinson,et al.  Further checkpoints in Th1 development. , 2002, Immunity.

[28]  T. Mcclanahan,et al.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. , 2002, Immunity.

[29]  A. Sher,et al.  T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  X. Hua,et al.  Cell cycle controlling the silencing and functioning of mammalian activators , 2001, Current Biology.

[31]  T. Mak,et al.  WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. , 2001, Immunity.

[32]  S. Akira,et al.  Cis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation , 2001, The Journal of experimental medicine.

[33]  T. Waldmann,et al.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. , 2001, Immunity.

[34]  R. Siegel,et al.  The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity , 2000, Nature Immunology.

[35]  F.J. Sauvage,et al.  Development of Th1-type immune responses requires the type I cytokine receptor TCCR , 2000, Nature.

[36]  H. Dickensheets,et al.  Interleukin-12 differentially regulates expression of IFN-gamma and interleukin-2 in human T lymphoblasts. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[37]  J. G. Zhang,et al.  Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Laurie H Glimcher,et al.  A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment , 2000, Cell.

[39]  S. Akira,et al.  Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. , 1998, Journal of immunology.

[40]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[41]  Werner Müller,et al.  Regulated expression of gp130 and IL-6 receptor alpha chain in T cell maturation and activation. , 1998, International immunology.

[42]  Chyung-Ru Wang,et al.  Helper T cell differentiation is controlled by the cell cycle. , 1998, Immunity.

[43]  M. Karin,et al.  Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. , 1998, Science.

[44]  J. Tschopp,et al.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. , 1998, Immunity.

[45]  A. Khoruts,et al.  A Natural Immunological Adjuvant Enhances T Cell Clonal Expansion through a CD28-dependent, Interleukin (IL)-2–independent Mechanism , 1998, The Journal of experimental medicine.

[46]  H. Gudmundsdottir,et al.  Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. , 1997, The Journal of clinical investigation.

[47]  S. Szabo,et al.  Regulation of the Interleukin (IL)-12R β2 Subunit Expression in Developing T Helper 1 (Th1) and Th2 Cells , 1997, The Journal of experimental medicine.

[48]  D. Carvajal,et al.  IL-12-Deficient Mice Are Defective in IFNγ Production and Type 1 Cytokine Responses , 1996 .

[49]  C. Hunter,et al.  Roles of gamma interferon and other cytokines in suppression of the spleen cell proliferative response to concanavalin A and toxoplasma antigen during acute toxoplasmosis , 1995, Infection and immunity.

[50]  R. Seder Acquisition of lymphokine-producing phenotype by CD4+ T cells. , 1994, The Journal of allergy and clinical immunology.

[51]  T. Mosmann,et al.  Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. , 1994, Journal of immunology.

[52]  C Anasetti,et al.  Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 , 1993, The Journal of experimental medicine.

[53]  R. Schwartz Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.

[54]  A. Sher,et al.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. , 1991, Journal of immunology.

[55]  F. Dumont,et al.  The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. , 1989, Journal of immunology.

[56]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[57]  D. Baltimore,et al.  T-cell-specific expression of interleukin 2: evidence for a negative regulatory site. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[58]  B. Luft,et al.  Demonstration of T-cell dysfunction during acute toxoplasma infection. , 1986, Cellular immunology.

[59]  V. Paetkau,et al.  Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. , 1984, Science.

[60]  S. Efrat,et al.  Control of biologically active interleukin 2 messenger RNA formation in induced human lymphocytes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[61]  武田 篤信 Cutting edge : Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment , 2003 .

[62]  A. Khoruts,et al.  In vivo activation of antigen-specific CD4 T cells. , 2001, Annual review of immunology.

[63]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[64]  K. Takakura,et al.  [Interleukin-2 receptor]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[65]  A. Rao,et al.  Transcriptional regulation of the IL-2 gene. , 1995, Current opinion in immunology.

[66]  W. Paul,et al.  Acquisition of lymphokine-producing phenotype by CD4+ T cells. , 1994, Annual review of immunology.